Medigen Vaccine Biologics Corp’s (高端疫苗) board of directors yesterday approved a proposal to conduct a phase 3 clinical trial of its COVID-19 vaccine in Europe, it said yesterday.
The final stage of human tests, if approved by the European Medicines Agency (EMA), would mark a big milestone in the COVID-19 vaccine development of Medigen, which has so far completed phase 1 and 2 clinical trials in Taiwan and is conducting a small phase 3 clinical trial in Paraguay.
Medigen in July consulted the EMA about conducting clinicial trials of its vaccine and it received a “positive response” from the agency, the company said in a statement.
Photo: Bloomberg
The EMA advised the company to conduct a phase 3 clinical trial directly in Europe instead of phase 1 or phase 2 trials, as the European regulator took into account that Medigen had completed earlier-stage human tests of the vaccine in Taiwan, company spokesman Leo Lee (李思賢) told by telephone.
The company is to finalize its design for the protocols of the phase 3 clinical trial in the near term and would apply to the EMA for permission to go ahead with it.
Although Medigen had researched how a third shot would bolster immunity by giving tens of participants in Taiwan a third dose, the company would still give two doses to those enrolled in its phase 3 trial in Europe, Lee said.
The number of participants in the clinical trial in Europe is expected to be 4,000 or fewer, and the trial would be conducted in multiple locations in multiple countries in Europe, it said.
“If everything goes smoothly, the clinical trial would begin in November and yield preliminary results in the first quarter next year,” Lee said.
It is possible that Medigen would be able to conduct an immunobridging study to compare the levels of antibodies in people who have received a Medigen vaccine against those who have been given one of the vaccines approved in Europe, the company said.
So far, the EMA has approved four COVID-19 vaccines for use in Europe: Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson; the first two are developed by the messenger RNA technology while the latter two are adenovirus-based vaccines, the EMA’s Web site showed.
Medigen’s vaccine is a protein-subunit vaccine, developed by the recombinant technology; the vaccine comprises recombinant spike protein of SARS-CoV-2 as the antigen to help a person’s body recognize the real virus if the person becomes infected, company data showed.
More than 20,000 employees at Apple Inc supplier Foxconn Technology Group’s (富士康) huge Chinese plant, mostly new hires not yet working on production lines, have left, a Foxconn source familiar with the matter said yesterday. The departures from the world’s largest iPhone factory dealt a fresh blow to the Taiwanese company, which has been grappling with strict COVID-19 restrictions that have fueled worker discontent and disrupted production ahead of Christmas and January’s Lunar New Year holiday. Concerns are mounting over Apple’s ability to deliver products for the busy holiday period as the worker unrest lingers at the Zhengzhou plant, which produces the
’INHERENT VULNERABILITIES’: The country has been working with the US to build its own lithium and rare earth mines in a bid to curb China’s dominance in the market Australia is vowing more assertive scrutiny of foreign investments in key commodities tied to electric vehicles and clean energy, in a potential warning to China which dominates the market. Australian Treasurer Jim Chalmers has asked the country’s Treasury to work with the Australian Foreign Investment Review Board and other stakeholders to undertake a review of foreign investment in sectors such as lithium and rare earths, he told a conference in Sydney yesterday. “We’ll need to be more assertive about encouraging investment that clearly aligns with our national interest in the longer term,” Chalmers said. Although Chalmers did not directly identify China investment as
FACTORY TUMULT: The departure of new workers impact production less than the quarantines imposed on existing employees, a worker at China’s ‘iPhone city’ said Turmoil at Apple Inc’s key manufacturing hub in Zhengzhou is likely to result in a production shortfall of almost 6 million iPhone Pro units this year, a person familiar with assembly operations said. The situation remains fluid at the plant and the estimate of lost production could change, the person said, asking not to be named discussing private information. Much depends on how quickly Hon Hai Precision Industry Co (鴻海精密), the Taiwanese company that operates the facility, can get people back to assembly lines after violent protests against COVID-19 restrictions. If lockdowns continue in the weeks ahead, production could be set further
HOLIDAY SEASON OMEN: Low-cost brands and high-end retailers had the most foot traffic, leaving mid-range stores struggling on what used to be their biggest sales day US retailers discounted heavily on Black Friday to clear out bloated inventories, but customers responded with only modest traffic, leaving profitability in doubt for many chains. Brick-and-mortar retailers, which were hit hard by COVID-19 closures and shoppers seeking to avoid the virus, saw in-store traffic on Friday tick up 2.9 percent from last year’s shopping event, data compiled by Sensormatic Solutions showed. US consumers are still spending, but they are growing more cautious after contending this year with the highest inflation rates in four decades. They are also keeping a sharper lookout for deals, and retailers — many of them still heavy
RSS